Breaking News Instant updates and real-time market news.

WFC

Wells Fargo

$56.02

-0.08 (-0.14%)

, C

Citi

$68.54

0.57 (0.84%)

09:09
07/13/18
07/13
09:09
07/13/18
09:09

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: JPMorgan (JPM), up fractionally. ALSO HIGHER: Advaxis (ADXS), up 36% after the FDA lifted the clinical hold on the company's Investigational New Drug application for its Phase 1/2 study of axalimogene filolisbac in combination with durvalumab for the treatment of patients with certain cervical cancers and HPV-associated head and neck cancer... Galmed (GLMD), up 14% after Stifel analyst Adam Walsh initiated the stock with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play"... Biocept (BIOC), up 18% after announcing a provider agreement with Alliance Global FZ to market and distribute Biocept's Target Selector liquid biopsy tests in the United Arab Emirates and several other countries... Gogo (GOGO), up 10% after announcing that it has completed a comprehensive analysis of its business and is considering splitting company and other strategic alternatives. DOWN AFTER EARNINGS: Wells Fargo (WFC), down 3%... Citi (C), down 1.6%. ALSO LOWER: Johnson & Johnson (JNJ), down 2% after a jury awarded $4.69B to 22 women who alleged that use of J&J talcum powder products caused their ovarian cancer... Ingredion (INGR), down 9% after cutting its FY18 guidance, citing lower than expected sweetener volumes sold into beverages and higher than expected manufacturing costs... Northrop Grumman (NOC), down 2% after chairman and chief executive officer Wes Bush announced plans to step down as CEO.

WFC

Wells Fargo

$56.02

-0.08 (-0.14%)

C

Citi

$68.54

0.57 (0.84%)

JPM

JPMorgan

$106.80

0.31 (0.29%)

JNJ

Johnson & Johnson

$127.77

1.77 (1.40%)

ADXS

Advaxis

$1.22

-0.12 (-8.96%)

GLMD

Galmed

$12.75

0.07 (0.55%)

BIOC

Biocept

$6.49

-2.18 (-25.14%)

GOGO

Gogo

$4.84

0.25 (5.45%)

INGR

Ingredion

$110.73

-0.32 (-0.29%)

NOC

Northrop Grumman

$322.13

10.44 (3.35%)

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 17

    Jul

  • 25

    Jul

  • 26

    Jul

  • 02

    Aug

  • 08

    Aug

  • 12

    Oct

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 15

    Oct

  • 15

    Oct

WFC Wells Fargo
$56.02

-0.08 (-0.14%)

07/02/18
07/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. RPM (RPM) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas saying he believes investors are now more willing to pay a higher multiple for RPM EBITDA because of new possibilities of cost reduction, changes in capital structure, or overall changes to the company given the involvement of activist Elliott Management. 2. Capital One (COF) upgraded to Outperform from Neutral at Credit Suisse with analyst Moshe Orenbuch citing improving credit quality, ahead of the industry. 3. Wells Fargo (WFC) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Betsy Graseck stating that the bank's passing the 2018 CCAR stress test removes an overhang and indicates to her that the Fed is receptive of the changes Wells is making. 4. ZTE Corp. (ZTCOY) upgraded to Buy from Underperform at Jefferies with analyst Edison Lee saying Li Zixue becoming Chairman of the Board is an important step toward meeting the conditions of the company's settlement with the U.S. 5. Curtiss-Wright (CW) upgraded to Outperform from Market Perform at William Blair with analyst Nicholas Heymann saying the valuation is "compelling" following the recent correction in the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/18
06/29/18
NO CHANGE

Goldman says Wells Fargo, Huntington, Regions among biggest winners of CCAR
Goldman Sachs analyst Richard Ramsden said the Fed's CCAR results came in largely better than expected, calling Wells Fargo (WFC), Huntington Bancshares (HBAN), Regions Financial (RF), SunTrust (STI) and Fifth Third (FITB) the biggest relative winners in his view. He believes the market will be focused on banks' 25% dividend growth announcements and believes the CCAR results can be a catalyst for a relief rally.
07/02/18
MSCO
07/02/18
UPGRADE
MSCO
Equal Weight
Wells Fargo upgraded to Equal Weight from Underweight at Morgan Stanley
07/02/18
07/02/18
UPGRADE
Target $62

Equal Weight
Wells Fargo upgraded to Equal Weight after CCAR test pass at Morgan Stanley
As previously reported, Morgan Stanley analyst Betsy Graseck upgraded Wells Fargo to Equal Weight from Underweight, stating that the bank's passing the 2018 CCAR stress test removes an overhang and indicates to her that the Fed is receptive of the changes Wells is making. Not only did Wells pass, the Fed approved buybacks that were almost twice her estimates, Graseck tells investors. Higher buybacks took her EPS estimate up 4% and Graseck raised her price target on Wells Fargo shares to $62 from $57.
C Citi
$68.54

0.57 (0.84%)

05/17/18
DAIW
05/17/18
DOWNGRADE
DAIW
Buy
Citi downgraded to Buy from Strong Buy at Daiwa
06/20/18
06/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Hold at Deutsche Bank. 2. BT Group (BT) upgraded to Buy from Hold at Jefferies with analyst Jeremy Dellis saying reducing the dividend to increase investment in fiber-to-the-premises networks to satisfy demands by British telecommunications regulator Ofcom could make BT a "geat deal more investable." 3. Duke Energy (DUK) upgraded to Buy from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing recent share underperformance and resolved regulatory overhangs. 4. Glatfelter (GLT) upgraded to Buy from Neutral at DA Davidson with analyst Steven Chercover saying he is "incrementally positive" on the stock based on his view of the announced acquisition of GP's European airlaid nonwoven business, which adds 35K tonnes per year in capacity to the company's existing 129K tpy. 5. Intelsat (I) upgraded to Outperform from Sector Perform at RBC Capital with analyst Wilton Fry citing his expected FCC release of the Notice of Proposed Rulemaking this week that will lead to adoption of the company's C-band proposal, "conservatively" estimating that this could add over $19 in earnings per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/18
DBAB
06/20/18
UPGRADE
Target $76
DBAB
Buy
Citi upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Matt O'Connor upgraded Citi (C) to Buy and raised his price target for the shares to $76 from $74. The analyst also calls Goldman Sachs (GS) and Wells Fargo (WFC) his top picks ahead of the Q2 reporting season.
06/29/18
OPCO
06/29/18
NO CHANGE
Target $88
OPCO
Outperform
Oppenheimer says 'particularly pleased' with Citi's $17.6B share buyback
Following the release of CCAR results for 2018, Oppenheimer analysts Chris Kotowski and Ben Chittenden told investors in a research note that they are "particularly pleased" with Citi's (C) $17.6B share buyback, up 13% from last year and above their $16.5B estimate, while the dividend increase to 45c was also 5c better than expected. The analysts noted that both Goldman (GS) and Morgan Stanley (MS) got "conditional passes" on their capital plans, as both banks "ran a bit afoul" of the supplementary leverage ratio limitation.
JPM JPMorgan
$106.80

0.31 (0.29%)

07/09/18
GSCO
07/09/18
NO CHANGE
GSCO
Bank of America, Morgan Stanley top ideas into Q2 earnings season, says Goldman Sachs
Goldman Sachs analyst Richard Ramsden expects Bank of America (BAC) and Morgan Stanley (MS) to beat consensus estimates in Q2. The analyst argues that both appear best positioned, while he sees risk for U.S. Bancorp (USB) and JPMorgan (JPM). Ramsden highlights Bank of America given the material valuation dislocation that looks to support the stock over time. Additionally, the analyst expects an expense and NII beat for Morgan Stanley.
06/21/18
BERN
06/21/18
NO CHANGE
BERN
Amazon/JPMorgan/Berkshire venture still negative for drug supply chain, says Bernstein
Bernstein analyst Lance Wilkes notes that Amazon (AMZN), Berkshire Hathaway (BRK.A; BRK.B) and JPMorgan (JPM) announced the appointment of Atul Gawande as the CEO of their new healthcare joint venture, effective July 9th. The analyst sees this appointment as indicating an emphasis on enablement of change in the system, along with thought and policy leadership, and believes the appointment of an operating oriented President or COO could refine the outlook for scope. Wilkes continues to see this venture as negative for drug supply chain and self-insured employer oriented MCOs.
06/29/18
DBAB
06/29/18
NO CHANGE
DBAB
Deutsche declares Wells Fargo, SunTrust, Huntington the CCAR winners
Deutsche Bank analyst Matt O'Connor views Wells Fargo (WFC), SunTrust (STI) and Huntington Bancshares (HBAN) as the winners of the Federal Reserve's Comprehensive Capital Analysis and Review. The banks separately disclosed planned dividend increases and buybacks for the next four quarters, O'Connor tells investors in a research note. He points out that while JPMorgan (JPM), KeyCorp (KEY) and M&T Bank (MTB) "all used the mulligan," he does not view this as negative.
06/08/18
BERN
06/08/18
NO CHANGE
BERN
Bernstein offers list of possible CEOs for Amazon-Berkshire-JPMorgan venture
After Berkshire' (BRK.A) Warren Buffett and JPMorgan's (JPM) Jamie Dimon announced on CNBC that they have selected a CEO for their healthcare joint venture with Amazon (AMZN) and added that they would announce the name in about two weeks, Bernstein analyst Lance Wilkes noted that Geisinger CEO David Feinberg denied accepting the position and said he is committed to Geisinger. The ultimate choice of the CEO will inform on the intended scope of the NewCo and how the companies will prioritize strategic direction and needed capabilities, said Wilkes, who offered a list of potential CEO candidates that includes Gary Loveman, Rick Jelinek, Matt Manders, Patrick Conway, Amir Rubin, Owen Tripp, Chris Grant, Marc Harrison, Andy Slavitt, Todd Park and Peter Orszag.
JNJ Johnson & Johnson
$127.77

1.77 (1.40%)

07/13/18
FBCO
07/13/18
NO CHANGE
Target $151
FBCO
Outperform
J&J verdict likely to increase attention on lawsuits, says Credit Suisse
After a Missouri jury on Thursday ordered Johnson & Johnson to pay $4.69B to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer, Credit Suisse analyst Vamil Divan said the large number of ongoing litigations are gaining the attention of investors and is not expected to slow. Given the number of cases related to both talc and mesh and the size of the potential verdicts, Divan says it is "challenging" to put reasonable ranges on what J&J's ultimate liability may end up being, though he notes that J&J has been able to overturn many of the cases and has appealed all of the unfavorable verdicts. Divan maintains an Outperform rating and $151 price target.
07/12/18
07/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the stock is down 10% year-to-date and 15% from its recent all-time high of $148. 2. Hallmark Financial (HALL) upgraded to Outperform from Market Perform at Raymond James. 3. Transocean (RIG), Ensco (ESV), and Rowan Companies (RDC) were upgraded to Buy from Hold at Tudor Pickering. 4. Precision Drilling (PDS) and Nabors Industries (NBR) were upgraded to Overweight from Equal Weight at Morgan Stanley. 5. CA Technologies (CA) upgraded to Market Perform from Underperform at Wells Fargo and Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/18
GSCO
07/12/18
UPGRADE
GSCO
Neutral
Johnson & Johnson upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $134. The shares closed yesterday down $1.11 to $126.24. The stock is down 10% year-to-date and 15% from its recent all-time high of $148, Rubin tells investors in a research note. She notes J&J is trading in line with the large cap Pharmaceuticals group at 15 times 2019 estimates. The company's non-operational earnings revisions are now better understood by investors at current share levels, Rubin contends. The analyst this morning also downgraded Perrigo (PRGO) to Sell from Neutral.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
ADXS Advaxis
$1.22

-0.12 (-8.96%)

06/13/18
JEFF
06/13/18
DOWNGRADE
Target $2
JEFF
Hold
Advaxis downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded Advaxis to Hold and cut his price target for the shares to $2 from $9. The analyst prefers to step to the sidelines pending proof-of-concept data. He sees no clear path to partnering for axalimogene filolisbac and notes efficacy data for the ADXS-NEO and ADXS-HOT programs are likely two years away.
06/13/18
06/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Square (SQ) downgraded to Neutral from Buy at Buckingham with analyst Chris Brendler saying he is taking a "breather" following the year-to-date share outperformance but raised his price target to $65 from $55. 2. Yelp (YELP) downgraded to Sell from Hold at Aegis. 3. AT&T (T) was downgraded to Sell from Neutral at MoffettNathanson while Time Warner (TWX) was downgraded to Neutral from Buy at the firm. Time Warner was also downgraded to Market Perform from Outperform at Barrington. 4. Comcast (CMCSA) downgraded to Market Perform from Outperform at Raymond James. 5. Advaxis (ADXS) downgraded to Hold from Buy at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/18
HCWC
03/14/18
NO CHANGE
Target $6
HCWC
Buy
Advaxis drug unlikely culprit of patient death, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Advaxis (ADXS) to $6 from $23 after the FDA placed a clinical hold on the Phase 1/2 study investigating the combination of the company's axalimogene filolisbac and AstraZeneca's (AZN) durvalumab for the treatment of HPV-associated cervical and head and neck cancers. Based on its previous safety profile, axalimogene is unlikely to be the cause of death for this patient, Ramakanth tells investors in a research note. The analyst, however, notes that it would likely take several months before the FDA is able to reach a decision and lift the clinical hold. He anticipates a one-to-two quarter delay to the axal plus durva combination therapy program but keeps a Buy rating on Advaxis shares.
03/13/18
CANT
03/13/18
NO CHANGE
Target $5
CANT
Overweight
Advaxis price target lowered to $5 from $19 at Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein lowered his price target for Advaxis to $5 after a clinical hold was placed on the Phase I/II AXAL plus durvalumab trial. The analyst, however, thinks it is "very possible" that the hold will be resolved. Further, Advaxis has sufficient capital into 2019, which is a "counterpoint to the clinical hold," Goldstein tells investors in a research note. She keeps an Overweight rating on Advaxis shares.
GLMD Galmed
$12.75

0.07 (0.55%)

07/11/18
CANT
07/11/18
INITIATION
Target $59
CANT
Overweight
Galmed initiated with an Overweight at Cantor Fitzgerald
Cantor analyst Elemer Piros initiated Galmed with an Overweight and $59 price target.
07/13/18
STFL
07/13/18
INITIATION
Target $35
STFL
Buy
Galmed initiated with a Buy at Stifel
Stifel analyst Adam Walsh initiated Galmed with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play" after Aramchol recently proved itself in a Phase 2 trial as a clearly active and "very safe" compound for treating NASH.
07/12/18
07/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Galmed (GLMD) initiated with an Overweight at Cantor Fitzgerald. 2. VF Corp. (VFC) initiated with a Buy at Deutsche Bank. 3. NetApp (NTAP) initiated with a Buy at Guggenheim. 4. Rayonier Advanced Materials (RYAM) initiated with a Buy at Berenberg. 5. Ebix (EBIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/18
CANT
07/12/18
INITIATION
Target $59
CANT
Overweight
Cantor puts $59 price target on 'undervalued' NASH play Galmed
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target. The stock closed yesterday down 45c to $10.55. The company is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fattyacid/bile-acid conjugates, Piros tells investors in a research note. The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol. Of the three drugs, Galmed's has the highest likelihood of achieving improvement on NASH resolution without worsening of fibrosis, and improvement in fibrosis score without worsening of NASH, Piros argues. He believes Galmed is undervalued relative to peers in the NASH space.
BIOC Biocept
$6.49

-2.18 (-25.14%)

05/23/18
WEST
05/23/18
DOWNGRADE
WEST
Neutral
Biocept downgraded to Neutral from Outperform at WestPark Capital
WestPark Capital analyst Lauren Chung downgraded Biocept to Neutral citing "limited funds to the balance sheet" following the company's Q1 results. The analyst wants to see an inflection in sales growth, or a strategic partnership, before getting more constructive on the shares.
04/04/18
WEST
04/04/18
NO CHANGE
Target $1
WEST
Outperform
Biocept price target lowered to $1 from $3 at WestPark Capital
WestPark Capital analyst Lauren Chung lowered her price target for Biocept to $1 following the company's Q4 results but maintains an Outperform rating on the name. While sales growth is slower than expected, Biocept continues to make "meaningful progress as an emerging pure play liquid biopsy diagnostics company," Chung tells investors in a post-earnings research note. Further, she views the Thermo Fisher collaboration as promising.
10/04/17
WEST
10/04/17
NO CHANGE
WEST
Biocept marketing agreement a positive, says WestPark Capital
WestPark Capital analyst Lauren Chung said Biocept's new promotion and marketing agreement with Miraca Life Sciences to market Biocept's tests and services in the U.S. will let Biocept to more aggressively boost sales without incurring material cost to the company, and could expand Biocept's reach for tests country wide. Chung rates Biocept a Buy with a $3 price target.
GOGO Gogo
$4.84

0.25 (5.45%)

04/11/18
WBLR
04/11/18
NO CHANGE
WBLR
Google interest ups chances of in-flight Wi-Fi acquisition, says William Blair
"We have seen this movie before" is what William Blair analyst Louie DiPalma says after Bloomberg reported yesterday that Google (GOOG, GOOGL) is in advanced talks to acquire Nokia's in-flight connectivity hardware business. Google joins a long list of technology, telecom, and media providers that have exhibited a strategic interest in in-flight Wi-Fi, "although all have thus far stayed on the perimeter," DiPalma tells investors in a research note. The analyst notes that incumbents Gogo (GOGO), Panasonic (PCRFY), ViaSat (VSAT), Global Eagle Entertainment (ENT), and Inmarsat (IMASY) have invested billions toward satellite capacity and infrastructure. The industry is all about scale and potential new entrants would not have any, DiPalma contends. He believes it would take any new entrant many years to build a network from scratch, obtain regulatory approvals, and procure line-fit partnerships. The analyst thinks Google's interest in in-flight connectivity increases the probability that a tech or telecom company would buy an incumbent in the space. DiPalma has Outperform ratings on ViaSat and Gogo and a Market Perform rating on Global Eagle.
05/30/18
MSCO
05/30/18
NO CHANGE
Target $3
MSCO
Underweight
Gogo price target lowered to $3 from $7 at Morgan Stanley
Morgan Stanley analyst Simon Flannery said Gogo's recent weak results raise questions about its underlying business, financial model and ability to generate positive free cash flow. Given his expectations for significantly lower commercial aviation North America revenue and profitability, Flannery cut his 2018 adjusted EBITDA estimate for Gogo by about 55% and his 2019/2020 estimates by about 15%. He lowered his price target on Gogo shares to $3 from $7 and maintains an Underweight rating on the stock.
05/21/18
UBSW
05/21/18
DOWNGRADE
Target $7
UBSW
Neutral
Gogo downgraded to Neutral from Buy at UBS
UBS downgraded Gogo to Neutral from Buy and lowered its price target to $7 from $14.
05/18/18
NORL
05/18/18
NO CHANGE
Target $1.5
NORL
Underperform
Gogo price target lowered to $1.50 from $3.50 at Northland
Norhtland analyst Paul Penney believes Gogo's issues remain "far reaching and deep," and as a result, cut estimates to take in account lower business and profitability levels. Penney said Gogo's excessive capex spending levels are not sustainable and expects continued equity erosion, leading the analyst to cut his price target to $1.50 from $3.50 and reiterate an Underperform rating.
INGR Ingredion
$110.73

-0.32 (-0.29%)

07/13/18
07/13/18
NO CHANGE
Target $145

Buy
Ingredion long-term thesis remains intact, says Jefferies
Jefferies analyst Akshay Jagdale says the long-term thesis on Ingredion remains intact despite the company's "disappointing" Q2 preannouncement. HFCS is a fairly small portion of Ingredion's overall portfolio and been in secular decline for some time, Jagdale tells investors in a research note. The analyst's long-term thesis is predicated more on Specialty business growth, which he says remains on track. Further, he believes the newly announced cost savings program should accelerate margin expansion. Jagdale reiterates a Buy rating on Ingredion with a $145 price target.
07/13/18
07/13/18
DOWNGRADE
Target $95

Sell
Ingredion downgraded to Sell after guidance cut at Citi
As previously reported, Citi analyst David Driscoll downgraded Ingredion to Sell from Neutral after the company lowered its Q2 and 2018 EPS forecast, stating that he expects the stock's valuation multiples to compress as investors sort through the number of issues that have come to light. He set a $95 price target on Ingredion shares.
07/13/18
SBSH
07/13/18
DOWNGRADE
SBSH
Sell
Ingredion downgraded to Sell from Neutral at Citi
06/27/18
VERF
06/27/18
UPGRADE
VERF
Buy
Ingredion upgraded to Buy from Hold at Vertical Group
NOC Northrop Grumman
$322.13

10.44 (3.35%)

06/21/18
JEFF
06/21/18
NO CHANGE
Target $400
JEFF
Buy
Northrop Grumman remains top defense pick at Jefferies
After meeting with management, Jefferies analyst Sheila Kahyaoglu says Northrop Grumman remains her top defense pick. Acquisition planning should allow Northrop to "hit the ground running" with the integration of Orbital ATK, Kahyaoglu tells investors in a research note. She believes the space business presents the biggest synergy opportunity and keeps a Buy rating on Northrop with a $400 price target.
06/27/18
FBCO
06/27/18
NO CHANGE
Target $341
FBCO
Neutral
Northrop Grumman price target raised to $341 from $326 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Northrop Grumman to $341 from $326 as he incorporates Orbital ATK now that the acquisition is closed. The analyst reiterates a Neutral rating on the shares.
06/22/18
BARD
06/22/18
NO CHANGE
Target $394
BARD
Outperform
Northrop Grumman should be bought on any weakness, says Baird
Baird analyst Peter Arment said he would be an aggressive buyer of Northrop Grumman (NOC) shares on any market weakness. The analyst updated his model to reflect the Orbital ATK (OA) deal, which is more favorable than he had previously been modeling. He said the strategic deal raises his top-line outlook. Arment reiterated his Outperform rating and $394 price target on Northrop Grumman shares.
05/22/18
FBCO
05/22/18
NO CHANGE
Target $326
FBCO
Neutral
Northrop Grumman price target lowered to $326 from $342 at Credit Suisse
Credit Suisse analyst Robert Spingarn lowered his price target for Northrop Grumman to $326 from $342 as he downgrades his outlook for Defense hardware stocks to neutral from bullish. The analyst reiterates a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
07/16/18
07/16
10:16
07/16/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
07/16/18
07/16
10:15
07/16/18
10:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

10:15
07/16/18
07/16
10:15
07/16/18
10:15
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

NFLX

Netflix

$399.49

3.57 (0.90%)

, PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

NFLX

Netflix

$399.49

3.57 (0.90%)

PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

ROK

Rockwell Automation

$168.02

-3.1 (-1.81%)

FDX

FedEx

$231.55

-2.2 (-0.94%)

HAS

Hasbro

$94.14

-2.365 (-2.45%)

XON

Intrexon

$14.90

-0.48 (-3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 23

    Jul

  • 25

    Jul

  • 17

    Sep

  • 20

    Sep

  • 21

    Sep

NFLX

Netflix

$399.49

3.57 (0.90%)

, PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NFLX

Netflix

$399.49

3.57 (0.90%)

PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

ROK

Rockwell Automation

$168.02

-3.1 (-1.81%)

FDX

FedEx

$231.55

-2.2 (-0.94%)

HAS

Hasbro

$94.14

-2.365 (-2.45%)

XON

Intrexon

$14.90

-0.48 (-3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 23

    Jul

  • 25

    Jul

  • 17

    Sep

  • 20

    Sep

  • 21

    Sep

WFC

Wells Fargo

$56.39

1.04 (1.88%)

, VFC

VF Corp.

$87.64

2.8 (3.30%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

WFC

Wells Fargo

$56.39

1.04 (1.88%)

VFC

VF Corp.

$87.64

2.8 (3.30%)

UPS

UPS

$111.28

2.3 (2.11%)

ALV

Autoliv

$106.19

0.46 (0.44%)

SAR

Saratoga Investment

$24.31

-0.32 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 20

    Jul

  • 23

    Jul

  • 06

    Aug

  • 07

    Aug

  • 08

    Aug

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

BAC

Bank of America

$29.10

0.565 (1.98%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Hot Stocks
Bank of America reports June default rate 2.66% vs. 2.98% last month »

Reports 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

RDY

Dr. Reddy's

$30.40

-2.86 (-8.60%)

10:13
07/16/18
07/16
10:13
07/16/18
10:13
Technical Analysis
Technical Take: Dr. Reddy's falls after injunction against Suboxone generic »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOGO

Gogo

$3.86

-0.17 (-4.22%)

10:10
07/16/18
07/16
10:10
07/16/18
10:10
Recommendations
Gogo analyst commentary  »

Gogo transformation plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$46.67

-0.885 (-1.86%)

10:10
07/16/18
07/16
10:10
07/16/18
10:10
Options
Repeat of bullish three-way spreads in 21st Century Fox »

Repeat of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

10:10
07/16/18
07/16
10:10
07/16/18
10:10
General news
U.S. business inventories rose 04% in May, with sales up 1.4%, as forecast »

U.S. business inventories…

CNXN

Connection

$34.08

(0.00%)

10:03
07/16/18
07/16
10:03
07/16/18
10:03
Downgrade
Connection rating change  »

Connection downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$308.63

-10.17 (-3.19%)

10:01
07/16/18
07/16
10:01
07/16/18
10:01
Technical Analysis
Technical Take: Tesla has a small potential bearish pattern »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:01
07/16/18
07/16
10:01
07/16/18
10:01
General news
Business Inventories data reported »

May Business Inventories…

SBH

Sally Beauty

$15.59

-0.78 (-4.76%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Sally Beauty falls -4.9% »

Sally Beauty is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

ADS

Alliance Data

$229.04

-14.45 (-5.93%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Alliance Data falls -5.9% »

Alliance Data is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

RDY

Dr. Reddy's

$30.50

-2.76 (-8.30%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Dr. Reddy's falls -8.1% »

Dr. Reddy's is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$7.20

0.39 (5.73%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Britannia Bulk rises 5.6% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$12.34

-0.42 (-3.29%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Options
3K Qep Resources Aug 13 - 14 call spreads bought for 33c »

3K Qep Resources Aug 13 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 19

    Aug

DB

Deutsche Bank

$12.11

0.865 (7.70%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Deutsche Bank rises 7.7% »

Deutsche Bank is up 7.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$19.17

1.78 (10.24%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Arconic rises 10.3% »

Arconic is up 10.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.29

-0.01 (-0.03%)

09:55
07/16/18
07/16
09:55
07/16/18
09:55
Downgrade
Honda rating change  »

Honda downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

VFC

VF Corp.

$87.06

2.22 (2.62%)

, PNC

PNC Financial

$139.80

2.46 (1.79%)

09:55
07/16/18
07/16
09:55
07/16/18
09:55
Options
Early notable gainers among liquid option names on July 16th »

Notable gainers among…

VFC

VF Corp.

$87.06

2.22 (2.62%)

PNC

PNC Financial

$139.80

2.46 (1.79%)

C

Citi

$68.39

1.39 (2.07%)

WFC

Wells Fargo

$56.41

1.06 (1.92%)

CFG

Citizens Financial

$40.02

0.66 (1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 20

    Jul

  • 20

    Jul

  • 26

    Jul

  • 12

    Oct

  • 19

    Oct

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 15

    Oct

  • 15

    Oct

IIIV

i3 Verticals

$16.73

(0.00%)

09:53
07/16/18
07/16
09:53
07/16/18
09:53
Initiation
i3 Verticals initiated  »

i3 Verticals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$353.66

2.85 (0.81%)

, GOL

Gol Linhas

$6.02

0.17 (2.91%)

09:53
07/16/18
07/16
09:53
07/16/18
09:53
Hot Stocks
Boeing, GOL Airlines sign order for 30 737 MAX 10 airplanes, 15 MAX 8s »

Boeing (BA) and GOL…

BA

Boeing

$353.66

2.85 (0.81%)

GOL

Gol Linhas

$6.02

0.17 (2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.